Indications up for PET

By Dylan Bushell-Embling
Wednesday, 16 July, 2008

The Australian Government has expanded approved indications for Medicare reimbursement for PET imaging.

The inclusion of ovarian cancer, colorectal cancer and recurrent melanoma brings to a total of six the number of PET indications which are approved for reimbursement through Medicare.

One company poised to take advantage of this decision is Cyclopharm [ASX: CYC], which has already commenced development of two PET radiopharmacy sites.

The first is to be built at the Macquarie University Private Hospital, and should be completed in the first half of next year.

Content from other channels on our network

You see what others miss

Tapping into the labour mobility market to fill ongoing workforce gaps

NSW cracks down on illegal tanning with first two successful prosecutions

Australian hospital workers' mobile phones carry deadly superbugs — study reveals

Bupa to acquire Partnered Health's 68 primary care and three urgent care clinics

Blade innovation reduces the cost of slicing and dicing

Hygienic Design in Practice: Supporting Modern Food Production

From Manual Weighing to Intelligent Quality Control with METTLER TOLEDO's IND400

Siemens and IFS announce Industrial AI partnership

Drunken Sailor — Scaling Smart with Packserv Automation

Pilot program reduces food waste in SEQ

Yarra Valley Water to report net zero operational emissions

Recycling workers' lives at risk from hazardous waste

Biochar used for solar water purification

Climate reporting period closes 30 June — what should businesses do next?

Indications up for PET

Australia's first cases of H5 avian influenza confirmed

AusBiotech partners with Tenmile

Australian CDC issues update in wake of Ebola outbreak

Content from other channels on our network